Search results for: Market Access
Filter search results
Biosimilars: Issues Overview
1 June 2010
…and makes unlikely the aggressive price competition on entry that has characterised the generics market. Overall, the number of biologics that have a large enough market share to attract biosimilars is…
The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?
25 June 2020
…best chances of securing safe and effective vaccines we need a payment mechanism using an Advance Market Commitment (AMC). He proposes a Benefit Based Advance Market Commitment (BBAMC). Crucially, this…
OHE’s AMR consultation response
21 November 2023
…products receiving a marketing authorisation in the period since the previous tender will be able to apply, as will products with a high probability of receiving a marketing authorisation within…
The Market for Biosimilars: Evolution and Policy Options
1 November 2008
…differences mean that biosimilar markets will evolve in a more complex way than traditional, small molecule, chemical generics markets. Regulators will need clinical trial evidence of efficacy and safety before…
Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison
1 June 2000
…in unregulated or less regulated markets, compared to strictly regulated markets. Second, regulation clearly undermines competition in the off-patent, multisource sector, which is contrary to sound economics and to the…
As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?
26 September 2018
…through clinical trials and to market. To drive the necessary investment, BRICS need to send a clear signal to the market that they are willing to pay for innovations that…
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
17 February 2015
…research. More generally, finding better mechanisms to enable differential pricing between and within LMICs is an important challenge for firms and policymakers. Access the full paper (open access) here….
How Does Pharmaceutical Spending Drive Innovation in Europe?
7 February 2022
…pharmaceutical spending without damaging incentives to innovate. Pharmaceutical innovation is a global activity impacted by revenues from different markets. The US is the most important market for many pharmaceutical investors…
OHE at ISPOR Philadelphia Part 2: Risk Sharing, Medical Breakthroughs, Early Access and Drug Development Costs
12 May 2015
…Philadelphia. This post is the second of a two part summary of OHE’s scheduled activity at ISPOR. Access the first blog post here. Risk Sharing / Performance-Based Arrangements for Drugs…